Pharmaceuticals News and Research

RSS

Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

Intellipharmaceutics International Inc. and its wholly owned subsidiary Intellipharmaceutics Corp. today announced that it and its licensee and development partner Par Pharmaceutical, Inc. ("Par") have received confirmation that the previously announced stays of the patent litigation concerning a generic version of Novartis' Attention Deficit Hyperactivity Disorder drug, Focalin XR®, (dexmethylphenidate hydrochloride), have expired without regulatory intervention, and that the parties have stipulated to a dismissal of the litigation.

15 May 2010

US Oncology Specialty passes VAWD accreditation program

US Oncology, Inc.'s Fort Worth, Texas distribution facility, US Oncology Specialty, LP, has once again successfully passed the National Association of Boards of Pharmacy Verified-Accredited Wholesale Distributors program's comprehensive criteria review and on-site inspection.

15 May 2010

RPS first-quarter service revenues increase 28.2% to $58.0M

ReSearch Pharmaceutical Services, Inc., a leading provider of integrated clinical development outsourcing solutions to the bio-pharmaceutical industry, announces its results for the quarter ended March 31, 2010. These statements include unaudited comparative results for RPS for the quarter ended March 31, 2009.

15 May 2010

Inhibitex commences trials on INX-189 for treatment of Hepatitis C infections

The first clinical trials have started on a new investigational drug, discovered by researchers at Cardiff University, which is being developed to treat infections caused by Hepatitis C virus.

15 May 2010

Hospira's I.V. administration set product line to be standardized to non-DEHP

Hospira, Inc., a leading global specialty pharmaceutical and medication delivery company, will expand its commitment to non-DEHP products by transitioning customers to its portfolio of non-DEHP intravenous administration sets.

15 May 2010

Research roundup: Whistleblowers, spreading best practices, Medicare's growth-limiting strategy

The Impact Of Removing Financial Incentives From Clinical Quality Indicators: Longitudinal Analysis Of Four Kaiser Permanente Indicators - The researchers found the removal of pay-for-performance incentives "was associated with a decrease in performance of about 3% per year on average for screening for diabetic retinopathy and about 1.6% per year for cervical cancer screening" (Lester et al., 5/11). More details about the study and related news coverage are in the May 12 Morning Report.

15 May 2010

Foundation Venture Capital Group makes initial investment of $175,000 to develop test to diagnose AD

As many as 5.3 million Americans, and 35 million people worldwide, are living with Alzheimer's disease, a devastating neurodegenerative illness characterized by memory loss, cognitive decline and widespread destruction of neurons in the brain. Today, there is no definitive diagnosis for the disease, and no treatment to cure it.

15 May 2010

Science special issue reports on Malaria

This week's issue of Science features news articles focusing on recent progress on malaria control in Africa and discussing future challenges, including drug resistance.

15 May 2010

Victory Pharma, Middlebrook Pharmaceuticals sign asset purchase agreement

MiddleBrook Pharmaceuticals, Inc. has entered into an asset purchase agreement with Victory Pharma, Inc. for the sale of substantially all of its assets, and assumption of trade sales and certain other liabilities, of the Company for approximately $17.1 million (the "Acquisition").

15 May 2010

Dyadic International reports $1.1 million net loss for first-quarter 2010

Dyadic International, Inc., a leading-edge biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the quarter ended March 31, 2010.

15 May 2010

Lotus Pharmaceuticals first-quarter net income up 38%

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China today reported its financial results for the first quarter ended March 31, 2010.

15 May 2010

FDA assigns Cadence Pharmaceuticals' OFIRMEV NDA new PDUFA action date

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has classified the OFIRMEV™ (acetaminophen) injection New Drug Application (NDA) resubmission as a complete Class 2 response to the FDA's February 10, 2010 action letter and assigned a new Prescription Drug User Fee Act (PDUFA) action date of November 4, 2010.

15 May 2010

FDA grants tentative approval for Teva's Cinacalcet HCl Tablets ANDA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Cinacalcet HCl Tablets 30, 60 & 90 mg.

15 May 2010

Nymox attributes increase in first-quarter net losses to higher clinical trial expenditures

Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009.

14 May 2010

BioSante Pharmaceuticals first-quarter net loss increases to $10.5 million

BioSante Pharmaceuticals, Inc. today reported on its recent developments and financial results for the first quarter, and its cash balance as of March 31, 2010.

14 May 2010

Nutrastar International's first-quarter 2010 revenues up 2.7%

Nutrastar International Inc., a leading nutraceutical company which produces and distributes Chinese Golden Grass and organic and specialty food products in China, today announced its financial results for the first quarter 2010.

14 May 2010

Hana Biosciences reports $5.5 million net loss for first-quarter 2010

Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.

14 May 2010

Caliper Life Sciences' CDAS unit awarded new funding commitment for EPA ToxCast screening program

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today announced that its Caliper Discovery Alliances and Services (CDAS) unit has been awarded a new funding commitment for $2.9 million under its contract with the Environmental Protection Agency for the EPA's ToxCast screening program.

14 May 2010

FDA grants tentative approval for Impax Laboratories' generic Opana ER

Impax Laboratories, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application (ANDA) for generic version of Opana® ER (oxymorphone hydrochloride) 5, 7.5, 10, 15, 20, 30 and 40 mg tablets.

14 May 2010

Clondalkin Group plans to strengthen its position in the European pharmaceutical and healthcare sector

International packaging producer Clondalkin Group has revealed plans to further strengthen its position in the European pharmaceutical and healthcare sector.

14 May 2010